BERG is engaged in the research and development of diagnostics, theranostics and patient therapeutics in the areas of oncology, endocrinology and neurology. All of our research and clinical trials employ the BERG Interrogative Biology® platform. This platform is deployed throughout the clinical process from identifying biomarkers for drug discovery to monitoring patient response and guiding our clinical trials. We can build models with the platform using the patient's own biology in order to stratify the population by response to the trial drug as well as monitor patient response over time at a biological level, which may lead to more successful trials.

 

 

Therapeutics Pipeline

 

BPM 31510
  • Intravenous Tumor | Mono Therapy
    DiscoveryPreclinicalPhase 1Phase 2Phase 3
    This is an open label trial evaluating BPM 31510 as a single agent in patients with advanced refractory solid tumors. This is a dose-finding trial currently on-going at the following clinical sites: Weill Cornell Medical College, MD Anderson Cancer Center, and Palo Alto Medical Center.
  • Intravenous Tumor | Combination Therapy
    DiscoveryPreclinicalPhase 1Phase 2Phase 3
    This is a Phase II open-label, non-randomized clinical trial is being conducted at Beth Israel Deaconess Medical Center, Mayo Clinic, the Medical College of Wisconsin and Vita Medical Associates.
  • Topical Squamous Cell Carcinoma | Mono Therapy
    DiscoveryPreclinicalPhase 1Phase 2Phase 3
    This Phase II trial in patients with Squamous Cell Carcinoma has been completed. A strategy for launch of late stage trials with this asset is currently being assessed.
BPM 31543
  • Topical alopecia
    DiscoveryPreclinicalPhase 1Phase 2Phase 3
    This is a dose escalation study to determine the maximum tolerated dose and the overall safety and tolerability of topical compound 31543 (Calcitriol) in patients who are scheduled to receive treatment with a taxane-based chemotherapy regimen. The trial is evaluating if topical Calcitriol is effective in preventing and/or diminishing chemotherapy-induced alopecia. Clinical sites include Memorial Sloan Kettering Cancer Center and Cedars Sinai Medical Center.

 

 

Diagnostics Pipeline

 

 
  • Prostate cancer | Multi-index diagnostic assay
    The panel addresses multiple clinical needs in detection and management of prostate cancer. Berg proprietary assay compliments the PSA test in prostate cancer screening, presents novel opportunities in non-invasive identification of the aggressive disease, and provides clinically actionable information in patient monitoring. The panel CLIA validation has been completed with ongoing prospective trials being conducted.
  • Heart Failure | Multi-analyte diagnostic assay
    The panel addresses multiple clinical needs in detection and management of Heart Failure. CLIA validation is ongoing and preliminary tests on retrospective samples have been completed.

 

 

Research & Development Pipeline

 

 
  • Cancer | Solid Tumor
    DiscoveryValidationPre-ClinicalIND
    Multiple pre-clinical targets - Post-discovery
  • Diabetes
    DiscoveryValidationPre-ClinicalIND
    Multiple pre-clinical targets - Post-discovery
  • Parkinson's Disease
    DiscoveryValidationPre-ClinicalIND
    Multiple pre-clinical targets - Post-discovery
  • Alzheimer's Disease
    DiscoveryValidationPre-ClinicalIND
    Multiple pre-clinical targets - Post-discovery
Elisa-Kits